Harrow Health, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-95.7% vs price
Base Case (Median)
-81.8% vs price
Bull Case (75th pct.)
-4.5% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $117.00 | 196.4% | High (40%) |
| EV/EBITDA | $11.25 | -71.5% | Medium (20%) |
| EV/FCF | $3.09 | -92.2% | Medium (20%) |
| Earnings Power Value | $-2.48 | -106.3% | Medium (50%) |
Based on 4 out of 8 methods, HROW appears overvalued at the current price of $39.48. The base case fair value of $7.17 implies 81.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.